ClinicalTrialsFinder
RecruitingPhase 4NCT04913870

Angiotensin Receptor Blockers in Aortic Stenosis

Impact of Angiotensin Receptor Blockers in Aortic Stenosis - a Randomized Controlled Trial

Sponsor

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Enrollment

144 participants

Start Date

Feb 1, 2020

Study Type

INTERVENTIONAL

Conditions

Aortic StenosisAortic Valve Stenosis

Summary

This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.

Eligibility

Min Age: 20 YearsMax Age: 99 Years

Inclusion Criteria4

  • Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and <4m/s)
  • Normal left ventricular ejection fraction (i.e. ≥50%)
  • Systolic blood pressure >110 mmHg
  • Diastolic blood pressure >70 mmHg

Exclusion Criteria11

  • More than mild aortic or mitral regurgitation, or mitral stenosis
  • Current use or documented indication for renin-angiotensin system medication or Aliskiren
  • Known allergy or intolerance to angiotensin II receptor blockers (ARBs)
  • Alzheimer, dementia or known non-compliant patient
  • Renal dysfunction (glomerular filtration rate <30ml/min/1.73m2)
  • Chronic hyperkalemia
  • Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment
  • Newly diagnosed (<2 months) or poorly controlled diabetes
  • Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (<3 months)
  • Pregnant or lactating women
  • Patients unable to read, understand or sign research consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAngiotensin Receptor Blockers

Angiotensin Receptor Blockers treatment for 2 years.

OTHERPlacebo

Placebo administration for 2 years.

Locations(2)

CRIUCPQ

Québec, Quebec, Canada

Odense University Hospital

Odense, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04913870

Related Trials

Hydra Single-centre Experience - Copenhagen, Denmark

NCT063426351 location

Patient Quality of Recovery After TAVR With Different Sedation Regimens

NCT075565231 location

Hydra Registry - Italy Experience

NCT059566524 locations

Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.

NCT064700221 location

Hydra Registry - UK

NCT065075794 locations